BANK VONTOBEL/CALL/NOVO NORDISK ADR B/200/0.1/17.01.25 | Market Closed - Boerse Frankfurt Warrants 19:04:31 17/05/2024 BST | ||
| 0.15 EUR | -10.71% |
|
| Current month | -23.47% | ||
| 1 month | -15.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.15 | -10.71% |
| 16/05/24 | 0.168 | -9.68% |
| 15/05/24 | 0.186 | +10.06% |
| 14/05/24 | 0.169 | -2.31% |
| 13/05/24 | 0.173 | +24.46% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 07:04 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD10NY |
| ISIN | DE000VD10NY7 |
| Date issued | 12/03/2024 |
| Strike | 200 $ |
| Maturity | 17/01/2025 (243 Days) |
| Parity | 10 : 1 |
| Emission price | 0.32 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.47 € |
|---|---|
| Lowest since issue | 0.116 € |
| Spread | 0.01 € |
| Spread % | 6.02% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Warrants
- Warrant
